Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

19
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
19
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

27
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
27
Dementia l: Introduction01:22

Dementia l: Introduction

29
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
29
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

16
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
16
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

68
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
68

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The potential of a selective anxiolytic afobazole in clinical practice].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[Transitional cognitive syndrome: Reconsidered classification of cognitive disorders].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[Rapidly progressive cognitive impairment as a single clinical manifestation of anti-NMDA receptor encephalitis].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[New Opportunities in the Treatment of Moderate Cognitive Impairment: Results of the Millennium Study in Real Clinical Practice].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[Clinical and kinematic analysis of swimming disorders in Parkinson's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[The patient pathway in the diagnosis and treatment of mild cognitive impairment and new therapeutic opportunities. Resolution of the Expert Council (Moscow, April 21, 2025)].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same journal

[The role of the cerebellum in the coordination of brain activity and the development of autism spectrum disorders].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same journal

[A clinical case of anxiety-hypochondriacal depression with extensive somatized symptoms in the elderly].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same journal

[De novo variant in the ATP2B2 gene as a cause of neuropsychiatric developmental disorder].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same journal

[Electroencephalographic predictors of olfactory stimulus discrimination in COVID-19 survivors].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same journal

[Effect of long-term carbamazepine therapy on bone metabolism in women with epilepsy].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same journal

[Glial-derived neurotrophic factor and neuropsychological status in COVID-19 survivors].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
See all related articles

Related Experiment Video

Updated: Apr 26, 2026

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

37.6K

[Primary progressive aphasias].

E E Vasenina1, O S Levin

  • 1GBOU DPO "Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia" MZ RF, Moskva.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|July 22, 2014
PubMed
Summary
This summary is machine-generated.

Primary progressive aphasias (PPA) are neurodegenerative disorders causing speech loss. Current treatments for agrammatic, logopenic, and semantic PPA variants show unclear efficacy despite research into neurochemical deficits.

More Related Videos

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

37.6K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K

Related Experiment Videos

Last Updated: Apr 26, 2026

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

37.6K
Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

37.6K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K

Area of Science:

  • Neuroscience
  • Neurology
  • Speech Pathology

Context:

  • Primary progressive aphasias (PPA) represent a group of neurodegenerative conditions.
  • These disorders are characterized by progressive deterioration of speech and language abilities.
  • Focal brain degeneration underlies the observed language deficits.

Purpose:

  • To outline the classification of primary progressive aphasias.
  • To highlight the heterogeneity within PPA based on clinical, imaging, and pathological data.
  • To discuss the challenges in developing effective treatments for PPA.

Summary:

  • Primary progressive aphasias (PPA) are classified into three main variants: agrammatic, logopenic, and semantic.
  • This classification is based on distinct clinical speech features, neuroimaging findings, and neuropathological characteristics.
  • Despite research into potential neurochemical deficits, clinical trials for PPA treatments have yielded inconclusive results.

Impact:

  • Improved understanding of PPA subtypes aids in differential diagnosis and targeted research.
  • Highlights the need for further investigation into neurochemical underpinnings for effective therapeutic strategies.
  • Underscores the current limitations in treating primary progressive aphasias, emphasizing the need for novel approaches.